0.753
price down icon0.76%   -0.0058
after-market Dopo l'orario di chiusura: .75 -0.003 -0.40%
loading

Revelation Biosciences Inc Borsa (REVB) Ultime notizie

pulisher
Nov 20, 2024

Warning: REVB is at high risk of performing badly - MSN

Nov 20, 2024
pulisher
Nov 12, 2024

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace

Nov 12, 2024
pulisher
Nov 12, 2024

Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com

Nov 11, 2024
pulisher
Nov 11, 2024

Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart

Nov 11, 2024
pulisher
Nov 11, 2024

REVB: Good Expense Control as Company Prepares for Trials - Research Tree

Nov 11, 2024
pulisher
Nov 11, 2024

Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews

Nov 11, 2024
pulisher
Nov 11, 2024

Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

REVB Results Set Stage for Future Growth - Yahoo Finance

Nov 11, 2024
pulisher
Nov 08, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Biosciences Inc (REVB) Quarterly 10-Q Report - Quartzy

Nov 08, 2024
pulisher
Oct 27, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN

Oct 27, 2024
pulisher
Oct 21, 2024

Revelation Biosciences faces Nasdaq delisting over noncompliance - Investing.com India

Oct 21, 2024
pulisher
Oct 03, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.43% - MSN

Oct 03, 2024
pulisher
Oct 02, 2024

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Oct 02, 2024
pulisher
Sep 25, 2024

A better buy-in window may exist right now for Revelation Biosciences Inc (REVB) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

Revelation Biosciences Inc Inc. (REVB) Price Performance: A Guide to Technical Indicators - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Farallon Capital Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Revolution Medicines added to Analyst Focus List at JPMorgan - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Morningstar

Sep 24, 2024
pulisher
Sep 24, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

A stock that deserves closer examination: Revelation Biosciences Inc (REVB) - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Revance Therapeutics Shares Fall on Crown Labs Deal Delay - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Financial Fitness Check: Examining Revelation Biosciences Inc (REVB)’s Key Ratios - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute - Seeking Alpha

Sep 23, 2024
pulisher
Sep 21, 2024

Revolve Group (NYSE:RVLV) Reaches New 1-Year High at $25.96 - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Revelation Biosciences stock hits 52-week low at $0.78 - Investing.com India

Sep 21, 2024
pulisher
Sep 21, 2024

Revelation Biosciences stock hits 52-week low at $0.78 By Investing.com - Investing.com Australia

Sep 21, 2024
pulisher
Sep 18, 2024

Revolution Medicines executive sells over $500k in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines COO sells over $191k in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines CFO sells over $99k in company stock - Investing.com India

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines executive sells over $200k in company stock - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines general counsel sells shares worth over $64k By Investing.com - Investing.com UK

Sep 18, 2024
pulisher
Sep 17, 2024

Renovaro faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

The growth track for Revolution Medicines Inc (RVMD) has changed recently - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Crown Labs tender offer for Revance delayed, expect deal to be completedanalyst - MSN

Sep 17, 2024
pulisher
Sep 17, 2024

Revelation Pharma Announces Revelation Wholesale, an Extension of Its National Compounding Network - PR Newswire

Sep 17, 2024
pulisher
Sep 17, 2024

455,099 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Sofinnova Investments Inc. - MarketBeat

Sep 17, 2024
pulisher
Sep 16, 2024

Revolve Group (NYSE:RVLV) Trading Down 5.2% - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - Seeking Alpha

Sep 16, 2024
pulisher
Sep 13, 2024

RVLV stock soars to 52-week high, touches $24.67 - Investing.com

Sep 13, 2024
pulisher
Sep 02, 2024

Financial Metrics Check: Revelation Biosciences Inc (REVB)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 02, 2024
pulisher
Aug 30, 2024

United States shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN

Aug 30, 2024
pulisher
Aug 26, 2024

Revelation Biosciences announces warrant exercise and inducement - Investing.com India

Aug 26, 2024
pulisher
Aug 25, 2024

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Manchestertimes

Aug 25, 2024
pulisher
Aug 23, 2024

Stock Performance Spotlight: Revelation Biosciences Inc (REVB) Ends the Day at 1.25, Down by -40.19 - The Dwinnex

Aug 23, 2024
pulisher
Aug 22, 2024

Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results - Benzinga

Aug 22, 2024
pulisher
Aug 22, 2024

Gold Down Over 1%; US Initial Jobless Claims Increase - Benzinga

Aug 22, 2024
pulisher
Aug 22, 2024

Revelation Biosciences Inc [REVB] Stock trading around $2.09 per share: What’s Next? - The DBT News

Aug 22, 2024
pulisher
Aug 22, 2024

Adversity is less terrifying than hope: Revelation Biosciences Inc (REVB) - SETE News

Aug 22, 2024
pulisher
Aug 21, 2024

Microsoft seeks to win over new players at gamer gathering - Yahoo Finance UK

Aug 21, 2024
pulisher
Aug 21, 2024

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - Yahoo Finance

Aug 21, 2024
pulisher
Aug 21, 2024

Keysight stock rising on Q3 earnings beat, upbeat guidance - Yahoo Finance

Aug 21, 2024
pulisher
Aug 21, 2024

Uniti Group Inc. to Participate at the Citi 2024 Global TMT Conference - Yahoo Finance

Aug 21, 2024
pulisher
Aug 21, 2024

Shein sues Temu alleging copyright infringement and fraud - Yahoo! Voices

Aug 21, 2024
pulisher
Aug 21, 2024

Yacht insurance provider OMAC is hull carrier for sunken yacht in Sicily, sources say - Yahoo News UK

Aug 21, 2024
pulisher
Aug 21, 2024

Ford delays BlueOval City truck launch date - Yahoo! Voices

Aug 21, 2024
pulisher
Aug 21, 2024

RNC’s Latest Fundraising Is a Sign of How Much Trump Is Struggling - Yahoo! Voices

Aug 21, 2024
pulisher
Aug 21, 2024

What is REVB’s price-to-sales ratio telling us about the company’s value? - US Post News

Aug 21, 2024
pulisher
Aug 21, 2024

CONSOL Energy Inc. and Arch Resources merge to create Core Natural Resources - Yahoo News

Aug 21, 2024
pulisher
Aug 21, 2024

Nvidia has a Buy rating from 66 analysts. Here's why - Yahoo Finance

Aug 21, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Capitalizzazione:     |  Volume (24 ore):